APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Group ACYW135 Meningococcal Polysaccharide Vaccine

Compare research editions
View pricing & licenses

Selected research

Industry Research

Group ACYW135 Meningococcal Polysaccharide Vaccine Industry Research Report 2026

Report ID 173996380529 December 2025123 pages

Choose your research edition.

Industry ResearchGroup ACYW135 Meningococcal Polysaccharide Vaccine Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Group ACYW135 Meningococcal Polysaccharide Vaccine Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Group ACYW135 Meningococcal Polysaccharide Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Group ACYW135 Meningococcal Polysaccharide Vaccine Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Group ACYW135 Meningococcal Polysaccharide Vaccine Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Group ACYW135 Meningococcal Polysaccharide Vaccine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Group ACYW135 Meningococcal Polysaccharide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Group ACYW135 Meningococcal Polysaccharide Vaccine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Group ACYW135 Meningococcal Polysaccharide Vaccine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Group ACYW135 Meningococcal Polysaccharide Vaccine include Zhejiang Tianyuan Biopharmaceutical Co., Ltd, Yuxi Watson Biotechnology Co., Ltd, CanSino Biologics AG, Hualan Biovaccine Co., Ltd, Chengdu Kanghua Biological Products Co., Ltd, Beijing Zhifei Luzhu Biopharmaceutical Co., Ltd, Beijing Institute of Biological Products Co., Ltd, Aimei Weixin Biopharmaceutical (Zhejiang) Co., Ltd and Walvax Biotechnology, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Group ACYW135 Meningococcal Polysaccharide Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Group ACYW135 Meningococcal Polysaccharide Vaccine Market by Company

Zhejiang Tianyuan Biopharmaceutical Co., Ltd

Yuxi Watson Biotechnology Co., Ltd

CanSino Biologics AG

Hualan Biovaccine Co., Ltd

Chengdu Kanghua Biological Products Co., Ltd

Beijing Zhifei Luzhu Biopharmaceutical Co., Ltd

Beijing Institute of Biological Products Co., Ltd

Aimei Weixin Biopharmaceutical (Zhejiang) Co., Ltd

Walvax Biotechnology

Sanofi-Pasteur

Group ACYW135 Meningococcal Polysaccharide Vaccine Segment by Type

Class I Vaccines

Class II Vaccines

Group ACYW135 Meningococcal Polysaccharide Vaccine Segment by Application

Hospital

Clinic

Group ACYW135 Meningococcal Polysaccharide Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Group ACYW135 Meningococcal Polysaccharide Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Group ACYW135 Meningococcal Polysaccharide Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Group ACYW135 Meningococcal Polysaccharide Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Group ACYW135 Meningococcal Polysaccharide Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Group ACYW135 Meningococcal Polysaccharide Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Group ACYW135 Meningococcal Polysaccharide Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Market Share by Manufacturers (2021-2026) Table 8. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue of Manufacturers (2021-2026) Table 9. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Group ACYW135 Meningococcal Polysaccharide Vaccine Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Group ACYW135 Meningococcal Polysaccharide Vaccine, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Group ACYW135 Meningococcal Polysaccharide Vaccine, Product Type & Application Table 14. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Group ACYW135 Meningococcal Polysaccharide Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Zhejiang Tianyuan Biopharmaceutical Co., Ltd Company Information Table 19. Zhejiang Tianyuan Biopharmaceutical Co., Ltd Business Overview Table 20. Zhejiang Tianyuan Biopharmaceutical Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Zhejiang Tianyuan Biopharmaceutical Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio Table 22. Zhejiang Tianyuan Biopharmaceutical Co., Ltd Recent Developments Table 23. Yuxi Watson Biotechnology Co., Ltd Company Information Table 24. Yuxi Watson Biotechnology Co., Ltd Business Overview Table 25. Yuxi Watson Biotechnology Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Yuxi Watson Biotechnology Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio Table 27. Yuxi Watson Biotechnology Co., Ltd Recent Developments Table 28. CanSino Biologics AG Company Information Table 29. CanSino Biologics AG Business Overview Table 30. CanSino Biologics AG Group ACYW135 Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. CanSino Biologics AG Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio Table 32. CanSino Biologics AG Recent Developments Table 33. Hualan Biovaccine Co., Ltd Company Information Table 34. Hualan Biovaccine Co., Ltd Business Overview Table 35. Hualan Biovaccine Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Hualan Biovaccine Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio Table 37. Hualan Biovaccine Co., Ltd Recent Developments Table 38. Chengdu Kanghua Biological Products Co., Ltd Company Information Table 39. Chengdu Kanghua Biological Products Co., Ltd Business Overview Table 40. Chengdu Kanghua Biological Products Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Chengdu Kanghua Biological Products Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio Table 42. Chengdu Kanghua Biological Products Co., Ltd Recent Developments Table 43. Beijing Zhifei Luzhu Biopharmaceutical Co., Ltd Company Information Table 44. Beijing Zhifei Luzhu Biopharmaceutical Co., Ltd Business Overview Table 45. Beijing Zhifei Luzhu Biopharmaceutical Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Beijing Zhifei Luzhu Biopharmaceutical Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio Table 47. Beijing Zhifei Luzhu Biopharmaceutical Co., Ltd Recent Developments Table 48. Beijing Institute of Biological Products Co., Ltd Company Information Table 49. Beijing Institute of Biological Products Co., Ltd Business Overview Table 50. Beijing Institute of Biological Products Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Beijing Institute of Biological Products Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio Table 52. Beijing Institute of Biological Products Co., Ltd Recent Developments Table 53. Aimei Weixin Biopharmaceutical (Zhejiang) Co., Ltd Company Information Table 54. Aimei Weixin Biopharmaceutical (Zhejiang) Co., Ltd Business Overview Table 55. Aimei Weixin Biopharmaceutical (Zhejiang) Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Aimei Weixin Biopharmaceutical (Zhejiang) Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio Table 57. Aimei Weixin Biopharmaceutical (Zhejiang) Co., Ltd Recent Developments Table 58. Walvax Biotechnology Company Information Table 59. Walvax Biotechnology Business Overview Table 60. Walvax Biotechnology Group ACYW135 Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Walvax Biotechnology Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio Table 62. Walvax Biotechnology Recent Developments Table 63. Sanofi-Pasteur Company Information Table 64. Sanofi-Pasteur Business Overview Table 65. Sanofi-Pasteur Group ACYW135 Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Sanofi-Pasteur Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio Table 67. Sanofi-Pasteur Recent Developments Table 68. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 69. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Region (2021-2026) & (K Units) Table 70. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Market Share by Region (2021-2026) Table 71. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Region (2027-2032) & (K Units) Table 72. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Market Share by Region (2027-2032) Table 73. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 74. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Market Share by Region (2021-2026) Table 75. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 76. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Market Share by Region (2027-2032) Table 77. North America Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 78. North America Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (K Units) Table 79. North America Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (K Units) Table 80. North America Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 81. North America Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 82. Europe Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. Europe Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (K Units) Table 84. Europe Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (K Units) Table 85. Europe Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 86. Europe Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 87. Asia Pacific Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. Asia Pacific Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (K Units) Table 89. Asia Pacific Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (K Units) Table 90. Asia Pacific Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 91. Asia Pacific Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 92. South America Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. South America Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (K Units) Table 94. South America Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (K Units) Table 95. South America Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 96. South America Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 97. Middle East and Africa Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Middle East and Africa Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (K Units) Table 99. Middle East and Africa Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (K Units) Table 100. Middle East and Africa Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 101. Middle East and Africa Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 102. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Type (2021-2026) & (K Units) Table 103. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Type (2027-2032) & (K Units) Table 104. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2021-2026) Table 105. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2027-2032) Table 106. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 107. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 108. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2021-2026) Table 109. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2027-2032) Table 110. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Price by Type (2021-2026) & (US$/Unit) Table 111. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Price by Type (2027-2032) & (US$/Unit) Table 112. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Application (2021-2026) & (K Units) Table 113. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Application (2027-2032) & (K Units) Table 114. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2021-2026) Table 115. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2027-2032) Table 116. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 117. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 118. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2021-2026) Table 119. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2027-2032) Table 120. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Price by Application (2021-2026) & (US$/Unit) Table 121. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Price by Application (2027-2032) & (US$/Unit) Table 122. Key Raw Materials Table 123. Raw Materials Key Suppliers Table 124. Group ACYW135 Meningococcal Polysaccharide Vaccine Distributors List Table 125. Group ACYW135 Meningococcal Polysaccharide Vaccine Customers List Table 126. Group ACYW135 Meningococcal Polysaccharide Vaccine Industry Trends Table 127. Group ACYW135 Meningococcal Polysaccharide Vaccine Industry Drivers Table 128. Group ACYW135 Meningococcal Polysaccharide Vaccine Industry Restraints Table 129. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Group ACYW135 Meningococcal Polysaccharide Vaccine Product Image Figure 5. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market Size (2021-2032) & (US$ Million) Figure 7. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales (2021-2032) & (K Units) Figure 8. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Average Price (US$/Unit) & (2021-2032) Figure 9. Class I Vaccines Product Image Figure 10. Class II Vaccines Product Image Figure 11. Hospital Product Image Figure 12. Clinic Product Image Figure 13. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Share by Manufacturers in 2025 Figure 14. Global Manufacturers of Group ACYW135 Meningococcal Polysaccharide Vaccine, Manufacturing Sites & Headquarters Figure 15. Global Top 5 and 10 Group ACYW135 Meningococcal Polysaccharide Vaccine Players Market Share by Revenue in 2025 Figure 16. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 18. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Region in 2025 Figure 19. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Region in 2025 Figure 20. North America Group ACYW135 Meningococcal Polysaccharide Vaccine Market Size by Country in 2025 Figure 21. North America Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Market Share by Country (2021-2032) Figure 22. North America Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Market Share by Country (2021-2032) Figure 23. United States Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 24. Canada Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Europe Group ACYW135 Meningococcal Polysaccharide Vaccine Market Size by Country in 2025 Figure 26. Europe Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Market Share by Country (2021-2032) Figure 27. Europe Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Market Share by Country (2021-2032) Figure 28. Germany Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. France Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. U.K. Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Italy Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Netherlands Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Asia Pacific Group ACYW135 Meningococcal Polysaccharide Vaccine Market Size by Country in 2025 Figure 34. Asia Pacific Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Market Share by Country (2021-2032) Figure 35. Asia Pacific Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Market Share by Country (2021-2032) Figure 36. China Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Japan Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. South Korea Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. India Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Australia Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. China Taiwan Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Southeast Asia Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Southeast Asia Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. South America Group ACYW135 Meningococcal Polysaccharide Vaccine Market Size by Country in 2025 Figure 45. South America Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Market Share by Country (2021-2032) Figure 46. South America Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Market Share by Country (2021-2032) Figure 47. Mexico Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Brazil Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Argentina Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Middle East and Africa Group ACYW135 Meningococcal Polysaccharide Vaccine Market Size by Country in 2025 Figure 51. Middle East and Africa Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Market Share by Country (2021-2032) Figure 52. Middle East and Africa Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Market Share by Country (2021-2032) Figure 53. Turkey Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Saudi Arabia Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. UAE Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2021-2032) Figure 57. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2021-2032) Figure 58. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Price (US$/Unit) by Type (2021-2032) Figure 59. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2021-2032) Figure 60. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2021-2032) Figure 61. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Price (US$/Unit) by Application (2021-2032) Figure 62. Group ACYW135 Meningococcal Polysaccharide Vaccine Value Chain Figure 63. Group ACYW135 Meningococcal Polysaccharide Vaccine Production Mode & Process Figure 64. Direct Comparison with Distribution Share Figure 65. Distributors Profiles Figure 66. Group ACYW135 Meningococcal Polysaccharide Vaccine Industry Opportunities and Challenges

Scope & coverage.

Types
  • Class I Vaccines
  • Class II Vaccines
Applications
  • Hospital
  • Clinic
Companies covered
  • Zhejiang Tianyuan Biopharmaceutical Co., Ltd
  • Yuxi Watson Biotechnology Co., Ltd
  • CanSino Biologics AG
  • Hualan Biovaccine Co., Ltd
  • Chengdu Kanghua Biological Products Co., Ltd
  • Beijing Zhifei Luzhu Biopharmaceutical Co., Ltd
  • Beijing Institute of Biological Products Co., Ltd
  • Aimei Weixin Biopharmaceutical (Zhejiang) Co., Ltd
  • Walvax Biotechnology
  • Sanofi-Pasteur

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market Size (2021-2032)
  4. 2.2.2 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales (2021-2032)
  5. 2.2.3 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market Average Price (2021-2032)
  6. 2.3 Group ACYW135 Meningococcal Polysaccharide Vaccine by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Class I Vaccines
  9. 2.3.3 Class II Vaccines
  10. 2.4 Group ACYW135 Meningococcal Polysaccharide Vaccine by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Hospital
  13. 2.4.3 Clinic
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Group ACYW135 Meningococcal Polysaccharide Vaccine, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Group ACYW135 Meningococcal Polysaccharide Vaccine, Product Type & Application
  8. 3.8 Global Manufacturers of Group ACYW135 Meningococcal Polysaccharide Vaccine, Established Date
  9. 3.9 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Zhejiang Tianyuan Biopharmaceutical Co., Ltd
  2. 4.1.1 Zhejiang Tianyuan Biopharmaceutical Co., Ltd Company Information
  3. 4.1.2 Zhejiang Tianyuan Biopharmaceutical Co., Ltd Business Overview
  4. 4.1.3 Zhejiang Tianyuan Biopharmaceutical Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Zhejiang Tianyuan Biopharmaceutical Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio
  6. 4.1.5 Zhejiang Tianyuan Biopharmaceutical Co., Ltd Recent Developments
  7. 4.2 Yuxi Watson Biotechnology Co., Ltd
  8. 4.2.1 Yuxi Watson Biotechnology Co., Ltd Company Information
  9. 4.2.2 Yuxi Watson Biotechnology Co., Ltd Business Overview
  10. 4.2.3 Yuxi Watson Biotechnology Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Yuxi Watson Biotechnology Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio
  12. 4.2.5 Yuxi Watson Biotechnology Co., Ltd Recent Developments
  13. 4.3 CanSino Biologics AG
  14. 4.3.1 CanSino Biologics AG Company Information
  15. 4.3.2 CanSino Biologics AG Business Overview
  16. 4.3.3 CanSino Biologics AG Group ACYW135 Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 CanSino Biologics AG Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio
  18. 4.3.5 CanSino Biologics AG Recent Developments
  19. 4.4 Hualan Biovaccine Co., Ltd
  20. 4.4.1 Hualan Biovaccine Co., Ltd Company Information
  21. 4.4.2 Hualan Biovaccine Co., Ltd Business Overview
  22. 4.4.3 Hualan Biovaccine Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Hualan Biovaccine Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio
  24. 4.4.5 Hualan Biovaccine Co., Ltd Recent Developments
  25. 4.5 Chengdu Kanghua Biological Products Co., Ltd
  26. 4.5.1 Chengdu Kanghua Biological Products Co., Ltd Company Information
  27. 4.5.2 Chengdu Kanghua Biological Products Co., Ltd Business Overview
  28. 4.5.3 Chengdu Kanghua Biological Products Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Chengdu Kanghua Biological Products Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio
  30. 4.5.5 Chengdu Kanghua Biological Products Co., Ltd Recent Developments
  31. 4.6 Beijing Zhifei Luzhu Biopharmaceutical Co., Ltd
  32. 4.6.1 Beijing Zhifei Luzhu Biopharmaceutical Co., Ltd Company Information
  33. 4.6.2 Beijing Zhifei Luzhu Biopharmaceutical Co., Ltd Business Overview
  34. 4.6.3 Beijing Zhifei Luzhu Biopharmaceutical Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Beijing Zhifei Luzhu Biopharmaceutical Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio
  36. 4.6.5 Beijing Zhifei Luzhu Biopharmaceutical Co., Ltd Recent Developments
  37. 4.7 Beijing Institute of Biological Products Co., Ltd
  38. 4.7.1 Beijing Institute of Biological Products Co., Ltd Company Information
  39. 4.7.2 Beijing Institute of Biological Products Co., Ltd Business Overview
  40. 4.7.3 Beijing Institute of Biological Products Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Beijing Institute of Biological Products Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio
  42. 4.7.5 Beijing Institute of Biological Products Co., Ltd Recent Developments
  43. 4.8 Aimei Weixin Biopharmaceutical (Zhejiang) Co., Ltd
  44. 4.8.1 Aimei Weixin Biopharmaceutical (Zhejiang) Co., Ltd Company Information
  45. 4.8.2 Aimei Weixin Biopharmaceutical (Zhejiang) Co., Ltd Business Overview
  46. 4.8.3 Aimei Weixin Biopharmaceutical (Zhejiang) Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Aimei Weixin Biopharmaceutical (Zhejiang) Co., Ltd Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio
  48. 4.8.5 Aimei Weixin Biopharmaceutical (Zhejiang) Co., Ltd Recent Developments
  49. 4.9 Walvax Biotechnology
  50. 4.9.1 Walvax Biotechnology Company Information
  51. 4.9.2 Walvax Biotechnology Business Overview
  52. 4.9.3 Walvax Biotechnology Group ACYW135 Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Walvax Biotechnology Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio
  54. 4.9.5 Walvax Biotechnology Recent Developments
  55. 4.10 Sanofi-Pasteur
  56. 4.10.1 Sanofi-Pasteur Company Information
  57. 4.10.2 Sanofi-Pasteur Business Overview
  58. 4.10.3 Sanofi-Pasteur Group ACYW135 Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Sanofi-Pasteur Group ACYW135 Meningococcal Polysaccharide Vaccine Product Portfolio
  60. 4.10.5 Sanofi-Pasteur Recent Developments
5 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market Scenario by Region
  1. 5.1 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Region: 2021-2032
  3. 5.2.1 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Region: 2021-2026
  4. 5.2.2 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Region: 2027-2032
  5. 5.3 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Region: 2021-2032
  6. 5.3.1 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Region: 2021-2026
  7. 5.3.2 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Region: 2027-2032
  8. 5.4 North America Group ACYW135 Meningococcal Polysaccharide Vaccine Market Facts & Figures by Country
  9. 5.4.1 North America Group ACYW135 Meningococcal Polysaccharide Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Country (2021-2032)
  11. 5.4.3 North America Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Group ACYW135 Meningococcal Polysaccharide Vaccine Market Facts & Figures by Country
  15. 5.5.1 Europe Group ACYW135 Meningococcal Polysaccharide Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Country (2021-2032)
  17. 5.5.3 Europe Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Group ACYW135 Meningococcal Polysaccharide Vaccine Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Group ACYW135 Meningococcal Polysaccharide Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Group ACYW135 Meningococcal Polysaccharide Vaccine Market Facts & Figures by Country
  35. 5.7.1 South America Group ACYW135 Meningococcal Polysaccharide Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Country (2021-2032)
  37. 5.7.3 South America Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Group ACYW135 Meningococcal Polysaccharide Vaccine Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Group ACYW135 Meningococcal Polysaccharide Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Type (2021-2032)
  2. 6.1.1 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2021-2032)
  4. 6.2 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Type (2021-2032)
  5. 6.2.1 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Application (2021-2032)
  2. 7.1.1 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2021-2032)
  4. 7.2 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue by Application (2021-2032)
  5. 7.2.1 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Group ACYW135 Meningococcal Polysaccharide Vaccine Value Chain Analysis
  2. 8.1.1 Group ACYW135 Meningococcal Polysaccharide Vaccine Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Group ACYW135 Meningococcal Polysaccharide Vaccine Production Mode & Process
  5. 8.2 Group ACYW135 Meningococcal Polysaccharide Vaccine Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Group ACYW135 Meningococcal Polysaccharide Vaccine Distributors
  8. 8.2.3 Group ACYW135 Meningococcal Polysaccharide Vaccine Customers
9 Global Group ACYW135 Meningococcal Polysaccharide Vaccine Analyzing Market Dynamics
  1. 9.1 Group ACYW135 Meningococcal Polysaccharide Vaccine Industry Trends
  2. 9.2 Group ACYW135 Meningococcal Polysaccharide Vaccine Industry Drivers
  3. 9.3 Group ACYW135 Meningococcal Polysaccharide Vaccine Industry Opportunities and Challenges
  4. 9.4 Group ACYW135 Meningococcal Polysaccharide Vaccine Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst